<DOC>
	<DOCNO>NCT00737282</DOCNO>
	<brief_summary>The safety Proellex 25 50 mg administer daily three treatment cycle ( four month ) evaluate .</brief_summary>
	<brief_title>Multicenter Study Evaluating Safety ProellexÂ® Premenopausal Women With Uterine Fibroids</brief_title>
	<detailed_description>Subjects randomize either Proellex dose , 25 mg 50 mg , 1:1 ratio . Subjects receive drug four ( 4 ) month cycle therapy three ( 3 ) time , treatment cycle separate off-drug interval menstruation occur . During treatment period , subject assess monthly . Subjects undergo additional follow-up 3 month follow last treatment visit .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Speak , read understand English Spanish ; Not undergone hysterectomy , uterine arterial embolization endometrial ablation therapy ( previous myomectomy acceptable ) cause surgical intervention uterine fibroid ( e.g . hysterectomy , myomectomy , uterine arterial embolization ) plan anticipate study ; One uterine fibroid must identifiable measurable transvaginal ultrasound ; Menstrual cycle last 24 36 day ; History excessive menstrual bleeding ; Negative urine pregnancy test screening . Additional inclusion criterion may apply . Six month ( immediately prior Screening Visit ) without menstrual period ; Prior hysterectomy ; Prior bilateral oophorectomy ; Pregnant lactate female woman attempt expect become pregnant time study ; Documented endometriosis , active pelvic inflammatory disease ( PID ) , platelet dysfunction , Von Willebrand 's Disease ; Any history diagnosis gynecological cancer cervical dysplasia grade include atypical squamous cell undetermined significance ( ASCUS ) associate Human Papilloma Virus ( HPV ) ; Subject diagnose suspect carcinoma breast , reproductive organ organ system ; Subject know active infection HIV , Hepatitis A , B C , Gonorrhea , Chlamydia previous history autoimmune disease positive serum antinuclear antibody . Additional exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine Fibroids</keyword>
</DOC>